Access to Prescription Digital Therapeutics Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458) is a legislative proposal introduced in the 118th Congress aimed at addressing the availability and use of prescription digital therapeutics. The bill was referred to the Subcommittee on Health but did not advance further and ultimately failed or expired. No official summary or full text is available, limiting detailed analysis. The bill falls under the health policy area and appears to focus on facilitating access to digital therapeutic tools prescribed by healthcare providers.
H.R. 1458 sought to improve access to prescription digital therapeutics but did not progress beyond subcommittee referral and expired without enactment.
- The bill is titled Access to Prescription Digital Therapeutics Act of 2023 and was introduced in the House of Representatives during the 118th Congress.
- It was referred to the Subcommittee on Health on December 17, 2024, but no further legislative action was recorded.
- The bill is categorized under health policy and aims to address issues related to prescription digital therapeutics, though specific provisions are unavailable.
['Patients who may receive prescription digital therapeutics as part of their healthcare.', 'Healthcare providers prescribing digital therapeutic treatments.', 'Digital therapeutics developers and companies involved in creating prescription digital health tools.', 'Health insurers and payers potentially involved in coverage decisions for digital therapeutics.']
['Lack of available full bill text and official summary limits understanding of implementation details and cost implications.', 'Unclear authority and oversight mechanisms due to missing legislative language.', 'Potential challenges in integrating digital therapeutics into existing healthcare and insurance frameworks.', 'Uncertainty about funding sources or reimbursement policies for prescription digital therapeutics.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and expired, indicating limited legislative momentum. The focus on digital therapeutics reflects growing interest in integrating technology into healthcare delivery, but the absence of further action suggests competing priorities or unresolved policy issues.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could encourage wider adoption of digital therapeutic technologies, potentially influencing healthcare delivery models.', 'May prompt insurers and healthcare providers to develop new coverage and reimbursement policies for digital therapeutics.', 'Could stimulate innovation and investment in the digital health sector by clarifying regulatory or access pathways.']
The absence of full bill text and an official summary limits transparency and public understanding of the bill's specific provisions and potential impacts. The bill's failure to advance beyond subcommittee referral highlights the importance of tracking legislative progress to assess policy relevance. Future efforts to improve access to digital therapeutics would benefit from clear, publicly available legislative documentation to facilitate oversight and informed debate.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.